This clinical trial is focused on studying the long-term safety and tolerability of a medication called secukinumab in individuals with Polymyalgia Rheumatica (PMR). PMR is a condition that causes muscle pain and stiffness, especially in the shoulders. The medication, secukinumab, is given as an injection under the skin and is being tested to see how safe it is for long-term use in people with this condition.

The purpose of the study is to monitor any side effects or serious side effects that may occur while using secukinumab. Participants in this study have previously completed a 52-week treatment period in an earlier study and have experienced a return of symptoms during a follow-up period without treatment. This study aims to provide further information on the safety of continuing secukinumab treatment over a longer period.

Participants will receive secukinumab injections and will be monitored for any adverse effects. The study will help determine if the benefits of using secukinumab outweigh any potential risks for individuals with PMR. The study is expected to continue until 2028, providing valuable data on the long-term use of this medication.